SLC1A2 and Cognitive impairment: Restoring GLT-1 expression by transgenic or pharmacological approaches in experimental animals significantly improved synaptic damage, Aβ deposition, and cognitive impairments (Takahashi et al., 2015; Mi et al., 2018).